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Epidemiology of Hepatic Angiosarcoma
in the United States: 1964-1974
by Henry Falk,*t John Herbert,* Steven Crowley,* Kamal
G. Ishak,* Louis B. Thomas,** Hans Popper § and Glyn
G. Caldwell*
A nationwide survey ofhepatic angiosarcoma (HAS) in the United States during the years 1964
through 1974 identified 168 cases. Ofthese, 42 cases (25%) were associated with known etiologic
factors, such asvinyl chloride monomer exposure during preparation ofpoly(vinyl chloride), use
of Thorotrast in angiography, exposure to inorganic arsenic, and treatment with androgenic-
anabolic steroids; 126 cases (75%) are ofuncertain etiology. HAS most often affects males (ratio
ofapproximately 3:1), peaks in the sixth and seventh decades oflife (somewhat earlierthan other
sarcomas of the liver) and appears to occur more often in the industrialized Northeast and
Midwest (although reporting artifact may be afactor). There is an extraordinary relative risk for
poly(vinyl chloride) polymerization workers; there may also be other chemical-industrial
associations that require further investigation. Prospective epidemiologic studies ofHAS should
be considered as a means ofidentifying other causative factors (e.g., chemicals or drugs) related
to HAS.
Introduction
This report is an overview of the nationwide
hepatic angiosarcoma (HAS) case-finding study for
the years 1964-1974 conducted by the Centers for
Disease Control (CDC).
At the start ofthis study, three causative factors
had been identified for HAS: vinyl chloride mono-
mer (VCM) (1, 2), Thorotrast (3), and inorganic
arsenic (4). The recently discovered association
between VCM and HAS has served as a stimulus
for this investigation, and multiple epidemiologic
studies of polyvinyl chloride (PVC) polymerization
*Chronic Diseases Division, Center for Environmental Health,
Centers for Disease Control, Public Health Service, U.S. Dept.
of Health and Human Services, Atlanta, Georgia 30333.
tAuthor to whom reprint requests should be addressed.
tDepartment of Hepatic Pathology, Armed Forces Institute
of Pathology, Washington, D.C. 20012.
**Laboratory of Pathology, National Cancer Institute, Na-
tional Institutes of Health, Bethesda, Maryland 20014.
§Stratton Laboratory for Liver Disease, Mount Sinai School
of Medicine of the City University of New York, New York
10029.
workers exposed to VCM have since demonstrated
very high relative risks for the development of
HAS (5, 6). Thorotrast is a colloidal suspension of
thorium dioxide, a radioactive alpha-emitter with
markedly prolonged radiologic and biologic half-
lives, which was used for carotid angiography and
liver-spleen scans in the period 1930-1955. The
thorium dioxide is sequestered by the reticuloendo-
thelial system, primarily in the Kupffer cells ofthe
liver; radiation injury to adjacent cells is the
presumed carcinogenic mechanism. Epidemiologic
studies of Thorotrast recipients have shown very
high relative risks for the development of HAS as
well as hepatocellular tumors (7, 8). The association
between arsenic and HAS is based on data from
several small autopsy series in German vintners in
the 1940s and 1950s (4, 9), which demonstrated an
increased incidence ofliverdisease, including HAS.
These workers were exposed to inorganic arsenical
pesticides during application of the pesticide and
also by drinking beverages prepared from the skins
of the sprayed grapes. Subsequently, HAS cases
were reported following long-term ingestion of
Fowler's solution (potassium arsenite) (10, 11) and
October 1981 107arsenic-contaminated well water (12). Individual
cases suggesting associations between HAS and
hemochromatosis (13) and copper exposure (14)
have also been reported.
Earlier reports from this study reviewed cases
associated with single causative factors (15-18),
including androgenic-anabolic steroids which we
feel are implicated as a fourth cause ofHAS (19). In
this paper, we present an overview of the case-
finding effort, placing the known causative factors
and cases of idiopathic origin in perspective.
Methods
Information relating to cases ofHAS occurring in
the United States during the years 1964 through
1974 was solicited by CDC in a variety of ways:
(1) announcements were placed in seven medical
journals; (2) a mailing was sent to all pathologists
in the country; (3) separate mailings were sent to
all state epidemiologists, major tumor referral
centers, and statewide tumor registries; (4) a death
certificate review for International Classification of
Diseases (ICD), Eighth Revision, Code 197.8 (liver
tumors, unspecified primary or secondary) for the
period 1966-1973 was conducted with the assistance
ofthe National Center for Health Statistics (NCHS)
and the 50 state health departments (Code 155.0,
primary liver tumors, was not reviewed because it
would have been impractical to obtain the much
larger number of certificates in this category and
because it was felt that the majority of cases of
HAS listed as such on the death certificate would
have been coded as 197.8); (5) arrangements were
made with the Armed Forces Institute of Pathol-
ogy (AFIP) to include cases in theirfiles (1943-1975)
in the review; (6) a number of cases were identified
from industrial surveys of PVC polymerization
workers and others potentially exposed to VCM;
and (7) permission was requested to include the
previously published cases of HAS occurring in
1964-1974.
The evaluation procedure for each identified case
was as follows: Initially, permission was requested
to review the appropriate pathologic specimens (all
submitted non-AFIP case material was reviewed at
the National Cancer Institute's Laboratory of Pa-
thologybyH. P. and L. B. T.). Followingconfirnation
of the diagnosis, the local physician was notified,
and, with his permission, the nearest of kin was
identified and contacted. Consent was obtained to
review medical records, and a questionnaire was
administered by telephone to obtain detailed occu-
pational, residential, and chemical exposure histo-
ries. In selected instances, friends, employers,
previous physicians orothers were alsointerviewed.
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In all, approximately 350 submitted cases were
reviewed by the pathology review group, some
outside our requested time period of 1964-1974.
Pathologic specimens were obtained for review in
approximately 95% of cases, many of which were
considered by our pathology panel not to be HAS.
Since survival after diagnosis is very brief and
many cases were only diagnosed at autopsy, we
have included all 168 confirmed cases with death
during 1964-1974 in the study group.
The above effort is essentially a case review.
Subsequently, the 22,432 death certificates obtained
from the review of Code 197.8 were used to carry
out a case-control study of occupation as recorded
on the death certificate in the following manner.
Death certificates were sought for all 168 confirmed
HAS cases; 166 were available. Controls were
sought from among the 22,432 death certificates in
ICD Eighth Revision Code 197.8 (liver tumor,
unspecified primary or secondary) that had been
obtained in the HAS case-finding effort (see above);
certificates of confirmed HAS cases were excluded
from the control selection process. Although deaths
in Code 197.8 might not represent the ideal control
group, the rationale was that these deaths resulted
from a broad variety of tumors of multiple sites
metastatic to the liver or represented cases which
were diagnostically uncertain; it was therefore
unlikely that any single diagnostic category would
predominate or that the occupational listings would
be heavily biased by any single group of cases.
Up to four controls (as many as were available)
were matched to each case , 30 years ofage on the
basis ofthe following criteria: age (+6 years), sex,
race, county of residence, and year of death (+3
years). One hundred thirty-five cases were success-
fully matched (79 of these had 4 matched controls;
the overall ratio of controls to cases was approxi-
mately 3:1). Individuals who could not be matched
were primarily young females and residents of
sparsely populated counties.
Acombined occupation and industry codingscheme
was developed to accommodate all listings recorded
on the certificates and to group listings on the basis
of potential hazardous exposures. The data were
analyzed by Rothman's method for matched groups
with multiple controls per case (20).
Results
Our study identified 168 deaths from confirmed
HAS during the years 1964 through 1974. For this
rare tumor, the best sources of case identification
were the pathologists, with the largest number of
cases identified through the single mailing to all
pathologists and the second largest numberofcases
Environmental Health Perspectivesidentified through pathology referral centers (par-
ticularly the AFIP).
Table 1 summarizes the results of the death
certificate review portion of the case-finding effort
and points up some ofthe inadequacies ofusingthis
method in epidemiologic studies of uncommon tu-
mors. Only 42% of the cases initially identified on
the death certificate as HAS were confirmed as
such on pathologic review; 50% of the cases were
confirmed not to be HAS. Furthermore, only 23%
of all the total cases in our study during the years
1966-1973 would have been identified by the death
certificate search alone. It can be seen that an
epidemiologic study based only on adeath certificate
searchofCode 197.8wouldhavebeenquiteinadequate.
Figure 1 compares age, race and sex data for the
confirmed HAS cases in our study with 131 cases of
non-angio hepatic sarcoma identified in the death
Table 1. HAS cases, CDC survey: death certificate review-
code 197.8 (8th revision ICD), 1966-1973
Length of review
7.5 years (1966-1971, 1973, 1/2 of 1972)
Total number of death certificates reviewed 22,432
Sarcomas of the liver, death certificate diagnoses:
Angiosarcoma (HAS) 74 (36.1%)
Leiomyosarcoma 24 (11.7%)
Fibrosarcoma 14 ( 6.8%)
Sarcoma (type unspecified) 64 (31.2%)
Sarcoma (other types) 29 (14.1%)
Total 205
Final pathologic diagnoses of 74 cases
identified on death certificate as HAS
Confirmed HAS
Confirmed not HAS
No pathology available
31 (42%)
37 (50%)
6 ( 8%)
certificate survey (these latter cases were not
confirmed by pathologic review). HAS has a strik-
ing male preponderance of approximately 3:1; this
is not true for other hepatic sarcomas. HAS also
appears to occur more often in younger age groups.
The higher proportion ofmales than females with
HAS first appears in the 40- to 49-year-old group
(Fig. 2) and is associated with a younger peak age
for males than females, although the mean age for
female HAS cases (50.1 years) is lowerthanthat for
males (57.9 years). These findings are not solely
related to the VCM-induced cases among polymer-
ization workers. The male preponderance is also
present in the Thorotrast, arsenic, and androgenic-
anabolic steroid associated cases, as well as in the
idiopathic cases (Table 2). Cases with known etiolo-
gy, however, have a younger age distribution than
idiopathic cases (Table 3), with a mean age of 51.0
years compared to 57.6 years for the idiopathic
cases.
Table 4 presents the 168 cases ofHAS by year of
death and etiologic status. The VCM-, Thorotrast-
and androgenic-anabolic steroid-associated cases
were more commonduringthelatterpartofthestudy
Table 2. HAS cases, CDC survey, 1964-1974: sex ratios,
etiologic categories.
Male Female Ratio
Vinyl chloride 12 0 (12 : 0)
Thorotrast 15 5 ( 3: 1)
Arsenic 4 2 ( 2: 1)
Androgenic-anabolic steroids 3 1 ( 3 : 1)
Subtotal 34 8 ( 4.3: 1)
Idiopathic 93 33 ( 2.8: 1)
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HAS (N=168)
MALE - 127 (76%)
FEMALE - 41 (24%)
WHITE - 155 (92%)
OTHER RACES- 13 (87.)
MALE - 67 (51 %)
FEMALE - 64 (49%) 1I / 1
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FIGURE 1. Hepatic angiosarcoma (HAS) cases compared with
non-angiohepatic sarcomacases, byagegroup: U.S., 1964-1974.
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FIGURE 2. Hepatic angiosarcoma cases, by age group and sex:
U.S., 1964-1974
109Table 3. HAS cases, CDC survey, 1964-1974: age distribution
for cases of known cause and for idiopathic cases.
Known etiology Idiopathic
Age, yr No. % No. %
0-9 1 (2) 2 (2)
10-19 0(-) 4 (3)
20-29 0(-) 1 (1)
30-39 4 (10) 8 (6)
40-49 8 (19) 19 (15)
50-59 22 (52) 24 (19)
60-69 4 (10) 39 (31)
70-79 3 ( 7) 21 (17)
:80 0(-) 8 ( 6)
Total 42 126
period. For the VCM- and androgenic-anabolic
steroid-associated cases, this is due to the rela-
tively recent introduction ofthese causative agents.
For the Thorotrast-induced cases, however, this
pattern was an unexpected finding. Based on the
originally calculated latent period ofapproximately
20 years (21), the general impression was that such
cases would be diminishing by 1975. However, the
number ofcases appeared to stillbe increasing as of
1974, apparently due to an increase in cases having
relatively low-dose angiographic procedures and
prolonged latentperiods (16). Thearsenic-associated
cases (including five adults with a history of pro-
longed use of Fowler's solution and one child with
environmental exposure) occurred primarily during
the earlier years of the study and may represent
the tail end of a larger problem in previous years.
The number ofidiopathic cases was low during the
first few years ofthe study (perhapsrelated to poor
recallbypathologists, and tothe factthatthe death
certificate search started with 1966). Case num-
bers, however, remained steady for most of the
study period except for a spurt in 1974. The latter
occurred right after the original report and the
attendant publicity of the first cases of VCM-
induced HAS (January 1974) and may be related to
improved diagnostic evaluation. Review of the
idiopathic cases occurring in 1974 demonstrated a
large number of elderly cases with no evidence of
clustering in a particular exposure setting.
The HAS mortality rate for the entire United
States during the study period was 0.75 cases per
107 population per year. Crude mortality rates by
region, based on county of residence at time of
diagnosis (Table 5), suggest a somewhat higher
incidence in the Northeast and in the industrial
portions ofthe Midwest. There was also anincrease
in the mountain region, although this is based on a
very small number of cases. The rates were low in
farming states and in the South; however, since
Table 4. HAS cases, CDC survey, 1964-1974: distribution by causative factors and year of death.
1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 Total
Idiopathic 4 10 9 13 12 13 11 12 13 11 18 126
Vinyl chloride 1 - - - 3 2 1 1 - 3 1 12
Arsenic 1 - 1 2 1 - - - - 1 - 6
Thorotrast - - - 1 2 2 3 2 4 1 5 20
Androgenic-anabolic steroids - 1 - _ _ 1 - 1 1 4
Total 6 10 10 17 18 17 15 16 17 17 25 168
Table 5. HAS cases, CDC survey, 1964-1974: distribution by region.
No. of cases No. of idiopathic cases
Region States Pop. 1970 (HAS/107/yr.) (idiopathicHAS/107/yr.)
1. New England ME, NH, VT, MA, RI, CT 11,847,186 12 (0.92) 9 (0.69)
2. Mid-Alantic NY, NJ, PA 37,152,813 38 (0.93) 28 (0.69)
3. E.N. Central OH, IN, IL, MI, WI 40,252,678 35 (0.79) 30 (0.68)
4. W.N. Central MN, LA, MO, ND, SD, NB, KS 16,324,389 10 (0.56) 9 (0.50)
5. S. Atlantic DE, MD, DC, VA, WV, NC,
SC, GA, FL 30,671,337 23 (0.68) 15 (0.44)
6. E.S. Central KY, TN, AL, MS 12,804,552 7 (0.50) 1 (0.07)
7. W.S. Central AR, LA, OK, TX 19,322,458 12 (0.56) 10 (0.47)
8. Mountain MT, ID, WY, CO, NM, AZ,
UT, NV 8,283,585 10 (1.10) 7 (0.77)
9. Pacific WA, OR, CA, AK, HI 26,525,744 21 (0.72) 17 (0.58)
Total 203,184,742 168 (0.75) 126 (0.56)
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majorhospital and tumor centers, it is possible that
low rural rates could be artifactual.
To summarize this portion of the study, it is
apparent that HAS has a strong male preponder-
ance, thatit appears to occur more often inyounger
age groups than other sarcomas of the liver, and
that there may be geographic differences which are
unrelated simply to the distribution ofVCM associ-
ated cases (the largest number of which were in
Kentucky and West Virginia). As part of the
follow-up effort we looked at occupation in the
death certificate case-control study. Table 6 shows
that the case-control ratios were elevated only for
the last two occupational categories. The first of
these (#7) shows a highly significant difference for
chemical workers that is entirely related to expo-
sure to VCM; all 10 cases were PVC polymerization
workers. The last category (#8) combined a large
number oflaboring groups with potential exposure
to a variety of chemicals; included are laborers,
machinists, maintenance workers and others. The
association ofthis heterogeneous grouping ofoccu-
pations with HAS is not statistically significant, nor
in reviewing the individual occupational data from
the interviews with family members were we able
to identify a specific chemical, plant, or process as a
causative factor. Nevertheless, taken together with
the earlier findings, this association suggests that
some chemical exposure or industrial factors may
be related to a portion ofthe idiopathic cases. Such
an association would not be unreasonable; machin-
ists, e.g., are potentially exposed to trichloroethyl-
ene (an experimental hepatocarcinogenthatis struc-
turally related to vinyl chloride), inorganic arsenic
and nitrosamines (which have been identified in
cutting fluids and are a known cause of HAS in
animals) (22, 23).
Discussion
A particularly intriguing feature of HAS is that
there are now four probable causes of this tumor,
and yet about 75% of the cases are of uncertain
etiology. Given that the HAS cases associated with
the four quite distinct etiologic factors (VCM,
Thorotrast, arsenic, and androgenic-anabolic ste-
roids) share a common morphologic progression to
HAS which is indistinguishable from that of idio-
pathic cases (24), it is likely that additional causal
factors are (or will be) associated with HAS. In this
study, the male preponderance, the younger age
distribution, the possible geographic relationship
with industrial portions of the country, and the
suggestion from the death certificate case-control
October 1981
study that groups with chemical exposure may be
at higher risk, raise the possibility that some ofthe
idiopathic cases may be related to presently
unidentified environmental or occupational expo-
sures.
This study and that of Baxter et al. (25) confirm
the limited diagnostic reliability ofdeath certificate
diagnosis ofHAS and the need to assess avarietyof
Table 6. Occupation as recorded on death certificate, case-
control study, CDC HAS survey, 1964-1974.
Occupation Cases Control
(N - 135) (N = 421)
Professional, technical,
engineers
Managers, administrators
Sales, wholesale/retail trade
Clerical
Communications
Finance, insurance, real
estate
Business, store owners,
proprietors
Service workers
Housewife, homemaker
Military, government
Unlisted, retired, disabled
Agricultural (farming,
stock, feed, fisherman)
Mining
Transport
Carpenters, craftsmen
Manufacturing (unspecified,
untitled, other)
Lumber, logging, wood
products
Metal, steel
Food, beverages, tobacco,
packing
Textiles
Paper, printing
Rubber/plastics
Automobile
Chemical
Machinist-metal cutter
Machine operators
Forgers, molders, casters
Painters
Sanitation, water works, power
Maintenance, custodians
Laborers
Construction
Heavy equipment operators
Repair services
Mechanics
16
5
3
9
1
2
5
8
18
2
5
74 (55%)
4 (3%)
1 (1%)
4 (3%)
2 (1%)
2
0
0
2
3
1
1
0
9 (7%)
10 (7%)
7
0
1
1
3
5
8
1
2
1
2
31 (23%)
40
23
29
13
5
4
11
36
58
3
12
234 (56%)
23 (5%)
8 (2%)
21 (5%)
9 (2%)
13
3
5
6
9
5
2
3
46 (11%)
1 (0%) a
p = 4.29 x 10-7
14
8
3
4
2
9
20
2
6
5
6
1 79 (19%)
p = o.11a
aStatistical analysis for case-control study with multiple
matches (20).
111sources ofdata in order to identify cases for studies
of rare tumors such as HAS.
The Thorotrast data are instructive because the
initial estimate ofthe latency period has lengthened
with time; recent cases have been in individuals
who had relatively low-dose procedures but pro-
longed latent periods (16). This accentuates the
need to continue evaluation ofVCM exposed groups
for the possible appearance of a similar pattern.
The time frame covered by our study is perhaps too
early to detect a sizable number of cases with
relatively low VCM exposure either in occupational
or environmental settings. In addition, Thorotrast-
induced HAS was noted approximately 10 years
before Thorotrast-induced hepatocellular tumors
were recognized; given the identical morphologic
appearance after VCM exposure, involving mixed
hyperplasia ofsinusoidal cells and hepatocytes, and
the occurrence of hepatocellular tumors in experi-
mental animals exposed to VCM (26), we need to
continue to follow-up VCM-exposed cohorts for the
possible appearance of hepatocellular tumors.
Cases of HAS associated with various factors
have previously been reported (14, 27, 28); individ-
ual cases associated with hemochromatosis, prior
radiotherapy, chloroprene exposure and chemother-
apy with urethane were also noted in this study,
but we have not discussed them in detail here.
Itwouldappearvaluabletocontinueepidemiologic
studies ofthis rare tumor. This might enable early
detection of additional etiologic factors for this
disease, such as the various structural analogs of
vinyl chloride (e.g., vinyl bromide and vinylidene
chloride) which have had industrial use. However,
because of the difficulty and time involved in
establishing adequate surveillance for rare tumors
such as HAS or mesothelioma, it would be best to
establish a single framework forstudying anumber
of rare tumors or marker illnesses at once. One
would then be able, e.g., to survey pathologists or
other groups at a single time to obtain information
on a variety of such conditions.
HAS is a rare tumor with at least four probable
causes and undoubtedly others that have not yet
been identified. Ascertainment of the range of
causative agents for HAS, as well as for more
common tumors, presents a challenge to epidemiol-
ogists.
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